Drug-Induced Hyperkalemia

Drug Safety

Volumn 37, Issue 9, 2014, Pages 677-692

  Ben Salem, Chaker ^a   Badreddine, Atef ^a   Fathallah, Neila ^a   Slim, Raoudha ^a   Hmouda, Houssem ^b  

^a FARHAT HACHED HOSPITAL   (Tunisia)

^b SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM;

ADVERSE DRUG REACTION; BLOOD; CHEMICALLY INDUCED; HUMAN; HYPERKALEMIA; PHYSIOLOGY;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYPERKALEMIA; POTASSIUM;

EID: 84929050073     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0196-1     Document Type: Review

References (129)

1. Sood MM, Sood AR, Richardson R. Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia. Mayo Clin Proc. 2007;82(12):1553–61.
2. Evans KJ, Greenberg A. Hyperkalemia: a review. J Intensive Care Med. 2005;20(5):272–90.
3. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000;109(4):307–14.
4. Miltiadous G, Mikhailidis DP, Elisaf M. Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Ther. 2003;8(4):267–76.
5. Passare G, Viitanen M, Torring O, Winblad B, Fastbom J. Sodium and potassium disturbances in the elderly: prevalence and association with drug use. Clin Drug Investig. 2004;24(9):535–44.
6. Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, et al. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Pharmacoepidemiol Drug Saf. 2011;20(7):747–53.
7. Banerjee A, Stoica C, Walia A. Acute hyperkalemia as a complication of intravenous therapy with epsilon-aminocaproic acid. J Clin Anesth. 2011;23(7):565–8.
8. Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant. 2004;19(9):2275–81.
9. Giovacchini G, Nicolas G, Freidank H, Mindt TL, Forrer F. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging. 2011;38(9):1675–82.
10. Hertz P, Richardson JA. Arginine-induced hyperkalemia in renal failure patients. Arch Intern Med. 1972;130(5):778–80.
11. Brass EP, Thompson WL. Drug-induced electrolyte abnormalities. Drugs. 1982;24(3):207–28.
12. Carroll HJ, Tice DA. The effects of epsilon amino-caproic acid upon potassium metabolism in the dog. Metabolism. 1966;15(5):449–57.
13. Nzerue CM, Falana B. Refractory hyperkalaemia associated with use of epsilon-aminocaproic acid during coronary bypass in a dialysis patient. Nephrol Dial Transplant. 2002;17(6):1150–1.
14. Lundborg P. The effect of adrenergic blockade on potassium concentrations in different conditions. Acta Med Scand Suppl. 1983;672:121–6.
15. Sica DA. Antihypertensive therapy and its effects on potassium homeostasis. J Clin Hypertens (Greenwich). 2006;8(1):67–73.
16. Bethune DW, McKay R. Paradoxical changes in serum-potassium during cardiopulmonary bypass in association with non-cardioselective beta blockade. Lancet. 1978;2(8085):380.
17. Swenson ER. Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist. Arch Intern Med. 1986;146(6):1220–1.
18. McCauley J, Murray J, Jordan M, Scantlebury V, Vivas C, Shapiro R. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol. 2002;22(4):347–51.
19. Castellino P, Simonson DC, DeFronzo RA. Adrenergic modulation of potassium metabolism during exercise in normal and diabetic humans. Am J Physiol. 1987;252(1 Pt 1):E68–76.
20. Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol. 1990;33:269–71.
21. Ben Salem C, Hmouda H, Bouraoui K. Drug-induced hypokalaemia. Curr Drug Saf. 2009;4(1):55–61.
22. Rasmussen L, Husted SE, Johnsen SP. Severe intoxication after an intentional overdose of amlodipine. Acta Anaesthesiol Scand. 2003;47(8):1038–40.
23. Imamura T, Matsuura Y, Nagoshi T, Ishikawa T, Date H, Kita T, et al. Hyperkalemia induced by the calcium channel blocker, benidipine. Intern Med. 2003;42(6):503–6.
24. Freed MI, Rastegar A, Bia MJ. Effects of calcium channel blockers on potassium homeostasis. Yale J Biol Med. 1991;64(2):177–86.
25. Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology. 2006;104(1):158–69.
26. Gronert GA. Succinylcholine-induced hyperkalemia and beyond. 1975. Anesthesiology. 2009;111(6):1372–7.
27. Buckley MS, Leblanc JM, Cawley MJ. Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. Crit Care Med. 2010;38(6 Suppl):S253–64.
28. Fenton F, Smally AJ, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med. 1996;28(4):440–1.
29. Manini AF, Nelson LS, Hoffman RS. Prognostic utility of serum potassium in chronic digoxin toxicity: a case-control study. Am J Cardiovasc Drugs. 2011;11(3):173–8.
30. Papadakis MA, Wexman MP, Fraser C, Sedlacek SM. Hyperkalemia complicating digoxin toxicity in a patient with renal failure. Am J Kidney Dis. 1985;5(1):64–6.
31. Moreno M, Murphy C, Goldsmith C. Increase in serum potassium resulting from the administration of hypertonic mannitol and other solutions. J Lab Clin Med. 1969;73(2):291–8.
32. Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth. 1987;34(5):442–6.
33. Sharma J, Salhotra R. Mannitol-induced intraoperative hyperkalemia, a little-known clinical entity. J Anaesthesiol Clin Pharmacol. 2012;28(4):546–7.
34. Tobita K, Kohno T. Case of hyperkalemia after the administration of hypertonic mannitol during craniotomy. Masui. 2010;59(5):641–4.
35. Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol. 2004;287(4):F593–601.
36. Staruschenko A. Regulation of transport in the connecting tubule and cortical collecting duct. Compr Physiol. 2012;2:1541–84.
37. Roscioni SS, de Zeeuw D, Bakker SJ, Lambers Heerspink HJ. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol. 2012;8(12):691–9.
38. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–92.
39. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158(1):26–32.
40. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531–48.
41. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75(12):793–5.
42. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156–66.
43. Cheng H, Harris RC. Potential side effects of renin inhibitors—mechanisms based on comparison with other renin-angiotensin blockers. Expert Opin Drug Saf. 2006;5(5):631–41.
44. Park I, Sheen SS, Lim HS, Yoon D, Park MY, Lee SH, et al. Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: a retrospective cohort study using a Korean clinical research database. Am J Cardiovasc Drugs. 2012;12(4):255–62.
45. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007;50(20):1959–66.
46. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–8.
47. Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26(5):1402–7.
48. Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia. 2011;54(1):44–50.
49. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42.
50. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–13.
51. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007;1(4):264–77.
52. White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich). 2010;12(10):765–75.
53. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8(6):669–81.
54. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis. 1996;28(1 Suppl 1):S56–62.
55. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med. 1999;107(6A):65S–70S discussion S-1S.
56. Preston RA, Hirsh MM, Oster MD Jr, Oster HM. University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia. Am J Ther. 1998;5(2):125–32.
57. Khanna A, White WB. The management of hyperkalemia in patients with cardiovascular disease. Am J Med. 2009;122(3):215–21.
58. Zimran A, Kramer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Br Med J (Clin Res Ed). 1985;291(6488):107–8.
59. Lafrance JP, Miller DR. Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study. Am J Kidney Dis. 2012;60(1):82–9.
60. Aljadhey H, Tu W, Hansen RA, Blalock S, Brater DC, Murray MD. Risk of hyperkalemia associated with selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf. 2010;19(11):1194–8.
61. Siebels M, Andrassy K, Vecsei P, Seelig HP, Back T, Nawroth P, et al. Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res. 1992;66(5):467–73.
62. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98(6):575–86.
63. Bhaskar B, Fraser JF, Mullaney D. Lest we forget: heparin-induced hyperkalemia. J Cardiothorac Vasc Anesth. 2012;26(1):106–9.
64. Gheno G, Cinetto L, Savarino C, Vellar S, Carraro M, Randon M. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol. 2003;59(5–6):373–7.
65. Aull L, Chao H, Coy K. Heparin-induced hyperkalemia. DICP. 1990;24(3):244–6.
66. Koren-Michowitz M, Avni B, Michowitz Y, Moravski G, Efrati S, Golik A. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Pharmacoepidemiol Drug Saf. 2004;13(5):299–302.
67. Danguy C, Biston P, Carlier E, Defrance P, Piagnerelli M. Severe hyperkalemia in critically ill patients treated with prophylactic doses of enoxaparin. Intensive Care Med. 2012;38(11):1904–5.
68. Marcelli JM, Lalau JD, Abourachid H, Quiret JC, Quichaud J. Unlike heparin, low-molecular weight heparin does not suppress aldosterone production. Horm Metab Res. 1989;21(7):402.
69. Rangel EB. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Expert Opin Drug Metab Toxicol. 2012;8(12):1531–48.
70. Caliskan Y, Kalayoglu-Besisik S, Sargin D, Ecder T. Cyclosporine-associated hyperkalemia: report of four allogeneic blood stem-cell transplant cases. Transplantation. 2003;75(7):1069–72.
71. Laine J, Holmberg C. Renal and adrenal mechanisms in cyclosporine-induced hyperkalaemia after renal transplantation. Eur J Clin Invest. 1995;25(9):670–6.
72. Heering P, Grabensee B. Influence of ciclosporin A on renal tubular function after kidney transplantation. Nephron. 1991;59(1):66–70.
73. Funder JW. Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade. Future Cardiol. 2006;2(5):535–41.
74. Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag. 2011;7:353–63.
75. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.
76. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, Investigators E. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118(16):1643–50.
77. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543–51.
78. Dinsdale C, Wani M, Steward J, O’Mahony MS. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing. 2005;34(4):395–8.
79. Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ. 2010;340:c1768.
80. Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. A report from the boston collaborative drug surveillance program. JAMA. 1973;225(1):40–3.
81. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297–303.
82. Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011;13(9):644–8.
83. Paterson JW, Dollery CT, Haslam RM. Amiloride hydrochloride in hypertensive patients. Br Med J. 1968;1(5589):422–3.
84. Chiu TF, Bullard MJ, Chen JC, Liaw SJ, Ng CJ. Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med. 1997;30(5):612–5.
85. Quan KC, Kahana L. Clinical experience with the diuretic effects of triamterene alone and combined with hydrochlorothiazide. Curr Ther Res Clin Exp. 1964;6:27–34.
86. Cohen AB. Hyperkalemic effects of triamterene. Ann Intern Med. 1966;65(3):521–7.
87. Petersen AG. Letter: dyazide and hyperkalemia. Ann Intern Med. 1976;84(5):612–3.
88. Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D’Andrea D, Szerlip H, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med. 1993;328(10):703–6.
89. Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol. 2009;5(4):193–202.
90. Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12(10):646–56.
91. Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf. 2000;22(3):227–36.
92. Ackerman BH, Patton ML, Guilday RE, Haith LR Jr, Stair-Buchmann M, Reigart CL. Trimethoprim-induced hyperkalemia in burn patients treated with intravenous or oral trimethoprim sulfamethoxazole for methicillin-resistant Staphylococcus aureus and other infections: nature or nurture? J Burn Care Res. 2013;34(1):127–32.
93. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2010;170(12):1045–9.
94. Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med. 1995;122(2):103–6.
95. Gabriels G, Stockem E, Greven J. Potassium-sparing renal effects of trimethoprim and structural analogues. Nephron. 2000;86(1):70–8.
96. Buff DD, Aboal AA. Pentamidine-associated renal dysfunction and hyperkalemia. Am J Med. 1990;88(5):552.
97. O’Brien JG, Dong BJ, Coleman RL, Gee L, Balano KB. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis. 1997;24(5):854–9.
98. Briceland LL, Bailie GR. Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. DICP. 1991;25(11):1171–4.
99. Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC. Hyperkalemia from single small oral doses of potassium chloride. Nephron. 1984;36(4):270–1.
100. Lawson DH. Adverse reactions to potassium chloride. Q J Med. 1974;43(171):433–40.
101. John SK, Rangan Y, Block CA, Koff MD. Life-threatening hyperkalemia from nutritional supplements: uncommon or undiagnosed? Am J Emerg Med. 2011;29(9):1237e1–2.
102. Doorenbos CJ, Vermeij CG. Danger of salt substitutes that contain potassium in patients with renal failure. BMJ. 2003;326(7379):35–6.
103. Ray K, Dorman S, Watson R. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. J Hum Hypertens. 1999;13(10):717–20.
104. Dent A, Walmsley D, Dhandapani S. Hyperkalaemia is a risk with low sodium salt in vulnerable patients. BMJ. 2011;343:d4514.
105. Lyons KS, McGlinchey P. Hyperkalaemic cardiac arrhythmia due to prolonged ingestion of potassium citrate. Int J Cardiol. 2009;131(3):e134–6.
106. Thiele A, Rehman HU. Hyperkalemia caused by penicillin. Am J Med. 2008;121(8):e1–2.
107. Chen J, Singhapricha T, Memarzadeh M, Ziman A, Yuan S, Hu KQ, et al. Storage age of transfused red blood cells during liver transplantation and its intraoperative and postoperative effects. World J Surg. 2012;36(10):2436–42.
108. Zimrin AB, Hess JR. Current issues relating to the transfusion of stored red blood cells. Vox Sang. 2009;96(2):93–103.
109. Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy. 1998;18(4):874–6.
110. Zaleski M, Dabage N, Paixao R, Muniz J. Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation. J Clin Pharmacol. 2013;53(4):456–8.
111. Marusic S, Gojo-Tomic N, Bacic-Vrca V, Bozikov V. Hyperkalaemia associated with hydroxyurea in a patient with polycythaemia vera. Eur J Clin Pharmacol. 2011;67(7):757–8.
112. Iglesias MH, Giesbrecht EM, von Dadelszen P, Magee LA. Postpartum hyperkalemia associated with magnesium sulfate. Hypertens Pregnancy. 2011;30(4):481–4.
113. Kitagawa H, Chang H, Fujita T. Hyperkalemia due to nafamostat mesylate. N Engl J Med. 1995;332(10):687.
114. Hata T, Hata K, Kawamura T. Severe hyperkalaemia with nafarelin. Lancet. 1996;347(8997):333.
115. Lee HH, Hsu PC, Lin TH, Lai WT, Sheu SH. Nicorandil-induced hyperkalemia in a uremic patient. Case Rep Med. 2012;2012:812178.
116. Adabala M, Jhaveri KD, Gitman M. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant. 2010;25(10):3439–42.
117. Tashiro M, Yoshikawa I, Kume K, Narita R, Sugihara Y, Otsuki M. Acute hyperkalemia associated with intravenous omeprazole therapy. Am J Gastroenterol. 2003;98(5):1209–10.
118. Gau JT, Heh V, Acharya U, Yang YX, Kao TC. Uses of proton pump inhibitors and serum potassium levels. Pharmacoepidemiol Drug Saf. 2009;18(9):865–71.
119. Lee JH, Ko YS, Shin HJ, Yi JH, Han SW, Kim HJ. Is There a Relationship between Hyperkalemia and Propofol? Electrolyte Blood Press. 2011;9(1):27–31.
120. Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH, Byrne JL. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol. 2003;122(1):160–1.
121. Panteliou E, Young N, Naysmith M. Life-threatening hyperkalemia following zoledronic acid infusion for Paget’s disease: a case report. J Med Case Rep. 2011;5:367.
122. Raebel MA, Ross C, Xu S, Roblin DW, Cheetham C, Blanchette CM, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med. 2010;25(4):326–33.
123. Bush TM, Shlotzhauer TL, Imai K. Nonsteroidal anti-inflammatory drugs. Proposed guidelines for monitoring toxicity. West J Med. 1991;155(1):39–42.
124. Hoskote SS, Joshi SR, Ghosh AK. Disorders of potassium homeostasis: pathophysiology and management. J Assoc Physicians India. 2008;56:685–93.
125. ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005;112(24 Suppl): IV1-203.
126. Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol. 1998;9(8):1535–43.
127. Chapagain A, Ashman N. Hyperkalaemia in the age of aldosterone antagonism. QJM. 2012;105(11):1049–57.
128. Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011;40(1):41–6.
129. Dick TB, Raines AA, Stinson JB, Collingridge DS, Harmston GE. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients. Transplant Proc. 2011;43(7):2664–8.